Statement: paclitaxel is the only drug in the primary trial given by IV.
Primary_evidence: INTERVENTION 1:    Treatment (Neoadjuvant Chemotherapy Before Surgery)   Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.   sunitinib malate: Given PO   paclitaxel: Given IV   doxorubicin hydrochloride: Given IV   cyclophosphamide: Given PO   filgrastim: Given SC   therapeutic conventional surgery: Undergo surgery   laboratory biomarker analysis: Correlative studies   flow cytometry: Correlative studies